Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Ratio: 2010-2021

Historic Equity Ratio for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to 0.67.

  • Neurocrine Biosciences' Equity Ratio rose 24.65% to 0.67 in Q3 2021 from the same period last year, while for Sep 2021 it was 0.67, marking a year-over-year increase of 24.65%. This contributed to the annual value of 0.65 for FY2020, which is 33.13% up from last year.
  • Neurocrine Biosciences' Equity Ratio amounted to 0.67 in Q3 2021, which was up 2.05% from 0.65 recorded in Q2 2021.
  • Neurocrine Biosciences' Equity Ratio's 5-year high stood at 0.85 during Q1 2017, with a 5-year trough of 0.43 in Q1 2019.
  • For the 3-year period, Neurocrine Biosciences' Equity Ratio averaged around 0.55, with its median value being 0.54 (2020).
  • Its Equity Ratio has fluctuated over the past 5 years, first slumped by 48.94% in 2017, then soared by 33.13% in 2020.
  • Quarterly analysis of 5 years shows Neurocrine Biosciences' Equity Ratio stood at 0.46 in 2017, then increased by 6.35% to 0.48 in 2018, then rose by 0.74% to 0.49 in 2019, then soared by 33.13% to 0.65 in 2020, then climbed by 24.65% to 0.67 in 2021.
  • Its Equity Ratio was 0.67 in Q3 2021, compared to 0.65 in Q2 2021 and 0.65 in Q1 2021.